Beam Therapeutics BEAM Ratios & Valuation
| FY'25 | FY'24 | FY'23 | FY'22 | ||
|---|---|---|---|---|---|
| Profitability | |||||
| Operating margin | -274.6%+380pp | -654.3%— | —— | -555.6%+201pp | |
| EBITDA margin | -258.6%+361pp | -619.7%— | —— | -532.4%+210pp | |
| Free cash flow margin | -257.7%+303pp | -560.8%— | —— | —— | |
| Returns | |||||
| Return on invested capital | -44.9%+17.6pp | -62.4%— | —— | -61.6%+68.1pp | |
| Efficiency | |||||
| Asset turnover | 0.1×+0.1× | 0×-0.2× | 0.3×+0.2× | 0×0.0× | |
| Liquidity | |||||
| Current ratio | 13.1×+8.3× | 4.8×-1.1× | 5.9×+1.0× | 4.9×-1.1× | |
| Quick ratio | 13.1×+8.3× | 4.8×-1.1× | 5.9×+1.0× | 4.9×-1.1× | |
| Cash ratio | 3×+1.5× | 1.5×-0.6× | 2.1×+1.1× | 1×-1.6× | |
| Leverage | |||||
| Debt-to-equity | 0.1×-0.1× | 0.2×0.0× | 0.2×-0.1× | 0.3×+0.1× | |
| Debt-to-assets | 0.1×0.0× | 0.1×0.0× | 0.1×0.0× | 0.1×0.0× | |
| Per Share | |||||
| Book value per share | $12.52+40.5% | $8.91-29.9% | $12.72+21.4% | $10.48-18.6% | |
| Valuation | |||||
| Market capitalization | $2.81B+37.0% | $2.05B-7.4% | $2.22B-19.5% | $2.76B-49.2% | |
| Enterprise value | $2.67B+38.2% | $1.93B-1.1% | $1.96B-27.8% | $2.71B-46.0% | |
| Price / sales | 20.1×-12.2× | 32.3×+26.5× | 5.9×-39.4× | 45.2×-59.5× | |
| Price / book | 2.3×-0.5× | 2.8×+0.5× | 2.3×-1.5× | 3.8×-2.8× | |
| EV / sales | 19.1×-11.3× | 30.4×+25.3× | 5.2×-39.3× | 44.4×-52.3× | |
| Free cash flow yield | -12.8%+4.5pp | -17.3%— | —— | —— |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Where do Beam Therapeutics's ratios come from?
- Every ratio is computed from Beam Therapeutics's SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.